These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3122488)

  • 1. Short course intermediate dose intravenous melphalan therapy in myeloma--relation to early emergence of drug resistance (phase II study).
    Sviland L; Leggat H; Harris AL; Bird G; Proctor SJ
    Acta Haematol; 1987; 78(4):233-8. PubMed ID: 3122488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-dose intravenous melphalan in advanced multiple myeloma.
    Bäck H; Lindblad R; Rödjer S; Westin J
    Acta Haematol; 1990; 83(4):183-6. PubMed ID: 2115714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide.
    Bergsagel DE; Cowan DH; Hasselback R
    Can Med Assoc J; 1972 Nov; 107(9):851-5. PubMed ID: 4653931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermediate-dose (25 mg/m2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment.
    Petrucci MT; Avvisati G; Tribalto M; Cantonetti M; Giovangrossi P; Mandelli F
    Eur J Haematol; 1989 Mar; 42(3):233-7. PubMed ID: 2924885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.
    Vigneau C; Ardiet C; Bret M; Laville M; Fiere D; Tranchand B; Fouque D
    J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I-II trial of high-dose melphalan in previously untreated stage III multiple myeloma: Cancer and Leukemia Group B study 8512.
    Case DC; Coleman M; Gottlieb A; McCarroll K
    Cancer Invest; 1992; 10(1):11-7. PubMed ID: 1735010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermediate dose of intravenous melphalan in advanced multiple myeloma.
    Tsakanikas S; Papanastasiou K; Stamatelou M; Maniatis A
    Oncology; 1991; 48(5):369-71. PubMed ID: 1745483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma treated with high dose intravenous melphalan.
    Selby PJ; McElwain TJ; Nandi AC; Perren TJ; Powles RL; Tillyer CR; Osborne RJ; Slevin ML; Malpas JS
    Br J Haematol; 1987 May; 66(1):55-62. PubMed ID: 3593657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral dosage of melphalan and response to treatment in multiple myeloma.
    Fernberg JO; Johansson B; Lewensohn R; Mellstedt H
    Eur J Cancer; 1990 Mar; 26(3):393-6. PubMed ID: 2141499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple myeloma. II. The value of melphalan.
    Bernard DB; Lynch SR; Bothwell TH; Bezwoda WR; Stevens K; Shulman G
    S Afr Med J; 1974 May; 48(24):1026-8. PubMed ID: 4835772
    [No Abstract]   [Full Text] [Related]  

  • 11. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.
    McElwain TJ; Powles RL
    Lancet; 1983 Oct; 2(8354):822-4. PubMed ID: 6137651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
    Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
    Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
    Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
    Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
    Popat R; Oakervee H; Williams C; Cook M; Craddock C; Basu S; Singer C; Harding S; Foot N; Hallam S; Odeh L; Joel S; Cavenagh J
    Br J Haematol; 2009 Mar; 144(6):887-94. PubMed ID: 19183191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
    Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
    Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral melphalan pharmacokinetics--relation to dose in patients with multiple myeloma.
    Ehrsson H; Eksborg S; Osterborg A; Mellstedt H; Lindfors A
    Med Oncol Tumor Pharmacother; 1989; 6(2):151-4. PubMed ID: 2747308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma.
    Moreau P; Fiere D; Bezwoda WR; Facon T; Attal M; Laporte JP; Colombat P; Haak HL; Monconduit M; Lockhorst H; Girault D; Harousseau JL
    J Clin Oncol; 1997 Feb; 15(2):660-6. PubMed ID: 9053491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [High-dose melphalan in patients with multiple myeloma].
    Moreau P; Le Bonniec M; Harousseau JL
    Bull Cancer; 1999 Mar; 86(3):283-8. PubMed ID: 10210762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of intravenous melphalan in patients with multiple myeloma.
    Brox L; Birkett L; Belch A
    Cancer Treat Rev; 1979 Jun; 6 Suppl():27-32. PubMed ID: 498169
    [No Abstract]   [Full Text] [Related]  

  • 20. Melphalan and its role in the management of patients with multiple myeloma.
    Falco P; Bringhen S; Avonto I; Gay F; Morabito F; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2007 Jul; 7(7):945-57. PubMed ID: 17627453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.